Vicore Pharma Holding AB Statistics
Vicore Pharma Holding AB (6Y4) Stock Statistics & Valuation Metrics
Total Valuation
Vicore Pharma Holding AB has a market cap or net worth of EUR 280.65M. The enterprise value is EUR 1.93B.
- Market Cap
- EUR 280.65M
- Enterprise Value
- EUR 1.93B
Share Statistics
Vicore Pharma Holding AB has 281,644,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 281,644,500
- Owned by Insiders
- ―
- Owned by Institutions
- 6.02%
Financial Efficiency
Vicore Pharma Holding AB’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -41.20%.
- Return on Equity (ROE)
- -0.44
- Return on Assets (ROA)
- -0.39
- Return on Invested Capital (ROIC)
- -41.20%
- Return on Capital Employed (ROCE)
- -0.41
- Revenue Per Employee
- 82.98K
- Profits Per Employee
- -10.38M
- Employee Count
- 46
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Vicore Pharma Holding AB is -5.72. Vicore Pharma Holding AB’s PEG ratio is -0.35.
- PE Ratio
- -5.72
- PS Ratio
- 774.28
- PB Ratio
- 3.62
- Price to FCF
- -10.32
- Price to Operating Cash Flow
- -6.79
- PEG Ratio
- -0.35
Income Statement
In the last 12 months, Vicore Pharma Holding AB had revenue of 3.82M and earned -477.47M in profits. Earnings per share was -1.99.
- Revenue
- 3.82M
- Gross Profit
- 3.82M
- Operating Income
- -454.44M
- Pretax Income
- -477.47M
- Net Income
- -477.47M
- EBITDA
- -477.41M
- Earnings Per Share (EPS)
- -1.99
Cash Flow
In the last 12 months, operating cash flow was -455.43M and capital expenditures 355.04M, giving a free cash flow of -299.51M billion.
- Operating Cash Flow
- -455.43M
- Free Cash Flow
- -299.51M
- Free Cash Flow per Share
- -1.06
Dividends & Yields
Vicore Pharma Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.56%
- Earnings Yield
- -16.04%
Stock Price Statistics
- Beta
- 0.92
- 52-Week Price Change
- 5.58%
- 50-Day Moving Average
- 0.87
- 200-Day Moving Average
- 0.93
- Relative Strength Index (RSI)
- 70.13
- Average Volume (3m)
- 2
Important Dates
Vicore Pharma Holding AB upcoming earnings date is Feb 25, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Vicore Pharma Holding AB as a current ratio of 10.31, with Debt / Equity ratio of 0.00%
- Current Ratio
- 10.31
- Quick Ratio
- 10.31
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.21
- Interest Coverage Ratio
- -9.03
Taxes
In the past 12 months, Vicore Pharma Holding AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Vicore Pharma Holding AB EV to EBITDA ratio is -4.99, with an EV/FCF ratio of -9.03.
- EV to Sales
- 676.84
- EV to EBITDA
- -4.99
- EV to Free Cash Flow
- -9.03
- EV to Operating Cash Flow
- -5.94
Balance Sheet
Vicore Pharma Holding AB has EUR 905.64M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 905.64M billion.
- Cash & Marketable Securities
- EUR 905.64M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 905.64M
- Net Cash Per Share
- EUR 3.22
- Tangible Book Value Per Share
- EUR 3.03
Margins
Gross margin is 80.97%, with operating margin of -13141.91%, and net profit margin of -12569.75%.
- Gross Margin
- 80.97%
- Operating Margin
- -13141.91%
- Pretax Margin
- -12563.27%
- Net Profit Margin
- -12569.75%
- EBITDA Margin
- -13560.62%
- EBIT Margin
- -13560.62%
Analyst Forecast
The average price target for Vicore Pharma Holding AB is EUR 3.54, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 3.54
- Price Target Upside
- 260.06% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- -53.21%
- EPS Growth Forecast
- -4.19%
